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Abstract: Obsessive–compulsive disorder (OCD) is a disabling and common neuropsychiatric 
condition of poorly known etiology. Many attempts have been made in the last few years to 
develop animal models of OCD with the aim of clarifying the genetic, neurochemical, and 
neuroanatomical basis of the disorder, as well as of developing novel pharmacological and 
neurosurgical treatments that may help to improve the prognosis of the illness. The latter goal is 
particularly important given that around 40% of patients with OCD do not respond to currently 
available therapies. This article summarizes strengths and limitations of the leading animal 
models of OCD including genetic, pharmacologically induced, behavioral manipulation-based, 
and neurodevelopmental models according to their face, construct, and predictive validity. On 
the basis of this evaluation, we discuss that currently labeled “animal models of OCD” should 
be regarded not as models of OCD but, rather, as animal models of different psychopathological 
processes, such as compulsivity, stereotypy, or perseverance, that are present not only in OCD but 
also in other psychiatric or neurological disorders. Animal models might constitute a challenging 
approach to study the neural and genetic mechanism of these phenomena from a trans-diagnostic 
perspective. Animal models are also of particular interest as tools for developing new therapeutic 
options for OCD, with the greatest convergence focusing on the glutamatergic system, the role 
of ovarian and related hormones, and the exploration of new potential targets for deep brain 
stimulation. Finally, future research on neurocognitive deficits associated with OCD through 
the use of analogous animal tasks could also provide a genuine opportunity to disentangle the 
complex etiology of the disorder.
Keywords: obsessive–compulsive disorder (OCD), genetic model, behavioral model, 
pharmacological model, compulsivity, perseverance
Introduction
Obsessive–compulsive disorder (OCD) is a disabling psychiatric condition 
characterized by the presence of upsetting, persistent thoughts, images, or impulses 
that are experienced as intrusive and senseless, and which cause marked distress 
or anxiety (obsessions) and/or excessive repetitive intentional behaviors or mental 
acts (compulsions) intended to neutralize this distress.1 The disorder has a lifetime 
prevalence of 2.3%,2 and it significantly interferes with social adjustment, employment, 
marriage, family relationships, and socioeconomic status.3,4
OCD is a clinically heterogeneous and etiologically complex condition,5 whose 
underlying pathophysiological mechanisms are still unknown. Successful treatment 
with selective serotonin reuptake inhibitors (SSRIs) alone or in combination 
with atypical antipsychotics suggests a role for serotonin and dopamine in the 
pathophysiology of OCD.6,7 Abnormalities in the dopaminergic system are also 
supported by the observation of obsessions and compulsions in basal ganglia-related 
Correspondence: Pino Alonso
OCD Clinical and Research Unit, 
Department of Psychiatry, Hospital de 
Bellvitge, c/Feixa Llarga s/n, Hospitalet de 
Llobregat, 08907 Barcelona, Spain
Tel +34 93 260 7659
Fax +34 93 260 7658
email mpalonso@bellvitgehospital.cat 




Running head verso: Alonso et al
Running head recto: Animal models of obsessive–compulsive disorder
DOI: http://dx.doi.org/10.2147/NDT.S62785
 
Powered by TCPDF (www.tcpdf.org)
                               1 / 1





disorders such as Tourette’s syndrome.8 The glutamatergic 
system has also been implicated in the pathophysiology of 
OCD, especially due to the observed association between the 
glutamate transporter gene SLCL1A1 and OCD9 (the most 
consistent and replicated finding of candidate gene studies 
in OCD), as well as due to the fact that OCD symptoms 
seem to improve in response to glutamatergic agents such 
as d-cycloserine10,11 (a partial N-methyl-d-aspartate [NMDA] 
agonist that facilitates the response to cognitive-behavioral 
therapy), riluzole12,13 (a glutamatergic antagonist), or 
memantine14 (a noncompetitive NMDA antagonist). Ovarian 
hormones have also been hypothesized to play a modulatory 
role in OCD, based on multiple reports of life events related 
to the female hormonal cycle triggering or exacerbating OCD 
symptomatology.15–18 Finally, genetic studies have broadened 
the number of neurotransmission systems implicated in 
susceptibility to OCD, with candidates including genes 
for the opioid system,19,20 as well as for growth-inducing 
messengers such as brain-derived neurotrophic factor.21,22
From a neuroanatomical point of view, neuroimaging 
research points to the involvement of parallel, partly 
segregated, cortico-striato-thalamo-cortical (CSTC) circuits 
in the pathophysiology of OCD. Milad and Rauch23 proposed 
three important CSTC circuits for OCD: the “affective 
circuit”, the “ventral cognitive circuit”, and the “dorsal cog-
nitive circuit”. The affective circuit, connecting the ventro-
medial prefrontal cortex (PFC) and anterior cingulate cortex 
(ACC) with the nucleus accumbens (NAC) and the thalamus, 
plays a role in affective and reward processing. The dorsal 
cognitive circuit, connecting the dorsolateral PFC, the 
caudate nucleus, and the thalamus, is crucial for executive 
functions such as working memory and planning. Finally, 
the ventral cognitive circuit, connecting the anterolateral 
orbitofrontal cortex (OFC), the anterior part of the puta-
men, and the thalamus, is involved in motor preparation and 
response inhibition. The OCD model proposes an imbalance 
between hyper-activated affective and ventral cognitive 
circuits (with dominance of the “direct pathway” that sends 
excitatory glutamatergic signals to the striatum, resulting 
in disinhibition of the thalamus and an increased excitatory 
effect on the cortex) and a hypo-activated dorsal cognitive 
circuit (with dominance of the indirect pathway, leading to 
increased inhibition of the thalamus and decreased excitation 
in the cortex).24 According to this model, hyper-activated 
ventral cognitive and affective circuits would be responsible 
for the increased anxiety and repetitive behaviors, while 
the hypo-activated dorsal cognitive circuit would explain the 
cognitive control deficits and inability to modulate emotional 
and behavioral responses present in OCD.25 Moreover, fron-
toparietal connections, mainly between the lateral prefrontal 
cortices and the inferior parietal lobe, are also important for 
optimal high-order cognitive processing, and both structural 
and functional abnormalities in parietal areas have been 
described in OCD samples.26
Stereotactic lesional procedures, mainly anterior cap-
sulotomy and anterior cingulotomy, significantly improve 
OCD symptoms in patients refractory to pharmacological 
and cognitive-behavioral treatments.27 The effectiveness of 
these ablative techniques is attributed to their modulatory 
effect upon the dysfunctional CSTC circuit described above.28 
Recently, electrical high-frequency brain stimulation at 
the ventral capsule/ventral striatum (VC/VS), the NAC, 
the subthalamic nucleus (STN), or the inferior thalamic 
peduncle has demonstrated similar effectivity in reducing 
OCD symptomatology in severely resistant patients.29
Animal models of OCD
Over the last 30 years, many attempts have been made to 
develop animal models of OCD under the hypothesis that, as 
in other neuropsychiatric disorders, they could be useful to 
disentangle the genetic, neurochemical, and neuroanatomical 
substrates of the disorder, as well as helping to develop novel 
treatments and to characterize the mechanism by which these 
treatments exert their beneficial influences.
In spite of these efforts, some authors have questioned 
whether it is actually possible to develop a true animal 
model of OCD.30 Their argument is based on the premise 
that the primary phenomena in OCD are obsessions, defined 
as recurrent, persistent, intrusive, and unwanted thoughts, 
ideas, or images that are subjectively resisted because they 
provoke marked anxiety or distress. As such, this kind of 
intrusive obsessional thoughts, about uniquely human topics 
(eg, being responsible for harm or mistakes, religion, moral-
ity, the fear of contamination), could never be accessed via 
animal models. However, animal models might be adequate 
for studying other aspects of OCD phenomenology, such as 
compulsivity, stereotypy, or perseveration. Compulsivity 
can be defined as the performance of repetitive, unwanted, 
and functionally impairing overt or covert behavior without 
adaptive function that is performed in a habitual or stereo-
typed fashion, either according to rigid rules or as a means of 
avoiding perceived negative consequences.31,32 In this sense, 
locomotion along relatively fixed paths and the display of 
specific motor rituals in specific locations are ingrained in the 
normal behavior of many animals including rodents, horses, 
pigs, cats, or dogs.33–35 This behavioral rigidity allows faster 
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performance and requires less attention, thus enabling more 
attention to be directed to other aspects of the environment, 
which may be crucial for the animal’s survival.36 Stereotypy, 
defined as the constancy of form in behavior produced 
through ritualization or uniform repetition of motor patterns, 
is also typically observed in wild animals in captivity, in farm 
animals, and after the administration of certain psychoactive 
drugs.36 However, authors critical of animal models point out 
that compulsive urges in OCD are not spontaneous phenom-
ena but, rather, provoked by obsessions. This implies that 
compulsive rituals are phenomenologically distinguishable 
from other repetitive, stereotypic behaviors, such as the 
stereotypies observed in pervasive developmental disorders, 
the tics observed in Tourette’s syndrome, and perseverative 
behaviors observed in patients with head injuries. It would 
therefore be difficult to determine, on the basis of behavioral 
observations alone, whether repetitive behaviors constitute 
true compulsions.30
Finally, some authors argue that notwithstanding the 
presence of obsessions and compulsions, OCD can be bet-
ter conceptualized as a consequence of overactive striatal 
habit-forming circuitry coupled with a lack of sufficient 
top-down control over these habits by higher cortical 
regions responsible for salient executive functions, including 
response inhibition and cognitive flexibility.37–39 Accord-
ing to this conception, animal models might provide the 
opportunity to analyze patterns of response and executive 
dysfunctions through the use of analogous neuropsychologi-
cal tests across species.40
Criteria for the validation 
and evaluation of animal models 
of psychiatric disorders
Animal models are experimental preparations developed 
in one species for the purpose of studying phenomena 
occurring in another species.41 According to McKinney 
and Bunney,42 the minimum requirements for an animal 
model are that symptoms induced in the model must be 
reasonably analogous to those seen in the modeled disease 
(what is referred to as face validity), that treatment modali-
ties effective in the modeled disease reverse the symptoms 
seen in animals (predictive validity), and that the neural 
systems involved and the mechanism, whether physiologi-
cal or psychological, underlying the behavioral symptoms 
observed in animals are similar to those responsible for the 
modeled disease (construct validity). Animal models can 
also be assessed in terms of reliability, defined as behavioral 
outputs of the model being robust and reproducible across 
laboratories.43 Some authors consider that the evaluation of 
animal models should principally rely on reliability and pre-
dictive validity, since face and construct validity are highly 
subjective and sometimes difficult or even impossible to test 
in animals.43 Moreover, even predictive validity is sometimes 
limited because of the lack of specificity of many medications 
in human patients.
An important issue to consider is the fact that an animal 
model will never mimic a psychiatric syndrome in its entirety. 
Therefore, the criteria that an animal model must satisfy to 
establish its validity will depend on the purpose of the model. 
For example, construct validity would be important for neuro-
biological research, whereas a model with predictive validity 
will be useful as a potential drug-screening tool.
Animal models can be classified according to different 
criteria. McKinney41 defined three groups: those designed 
to simulate a specific sign or symptom of a human disorder 
(behavioral similarity models), those designed to permit 
preclinical drug evaluations (empirical validity models), 
and those designed to evaluate a specific etiological theory 
(theory-driven models). Matthysse44 described four types 
based on principles of symptom similarity, pharmacological 
isomorphism, cross-species psychological processes, and 
gene transfer. Finally, Willner45 classified them into screening 
tests, behavioral bioassays, and simulations.
Face validity
Face validity is defined as the phenomenological similarity 
between the behavior in the animal model and the specific 
symptoms of the human condition. Face validity of animal 
models of OCD is based, by definition, on the induction of 
behaviors that are proposed to be similar to compulsions, 
that is, that are repetitive, excessive, and inappropriate. 
However, as already noted, some animal models can mimic 
other aspects of OCD such as perseveration. The most notable 
in this regard is the 8-hydroxy-2-(di-n-propylamino)-tetralin 
hydrobromide (8-OHDPAT) model. Only 8-OHDPAT-
induced perseveration has shown pharmacological similarity 
with OCD, whereas perseveration in other tasks, such as the 
stop-signal reaction time task46 or the reversal learning task,47 
has not shown this property. It should be noted, however, 
that perseveration is common in neurological and psychiatric 
conditions other than OCD, notably Parkinson’s disease, 
schizophrenia, or depression.
Construct validity
An animal model is considered to show proper construct 
validity if the physiological or psychological mechanisms 
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responsible for the behavioral symptoms observed in animals 
and the neural systems involved in them are similar to those 
known to be implicated in the human illness that is intended 
to be modeled. For animal models of OCD, this would imply 
demonstrating the involvement of the OFC, ACC, or basal 
ganglia, as well as the serotonergic, dopaminergic, and 
glutamatergic systems and ovarian hormones in the appear-
ance or modulation of the behavioral symptoms in animals. 
However, this is a complex issue in the context of OCD, 
since despite the numerous genetic, neurochemical, and neu-
roimaging studies that have been carried out in patients with 
OCD, the etiopathogenic basis of the disorder remains poorly 
understood. Consequently, an alternative way of generating 
new animal models of OCD with adequate construct validity 
has been proposed from the perspective of recent cognitive 
theories. This approach would involve consideration of the 
cognitive deficits typical of OCD (ie, flexibility, reversal 
learning) by means of neuropsychological tasks that could 
be analyzed by creating equivalent versions for animals and 
humans, for example, the stop-signal reaction time task or 
the intradimensional/extradimensional shift task.37–39
Predictive validity
For animal models of OCD, predictive validity is established 
by demonstrating selective alleviation of symptoms by 
administration of SSRIs and non-selective serotonin reuptake 
inhibitors (SRIs), as well as by demonstrating the efficacy 
of high-frequency stimulation of the STN and VC/VS. 
However, given that 40% of OCD patients do not respond to 
SSRIs, the demonstration of a lack of effect of drugs such as 
non-serotonergic antidepressants or benzodiazepines, which 
are not effective in OCD but are effective in other conditions 
that are responsive to SSRI treatment, such as depression, 
generalized anxiety disorder, or panic disorder, is more 
critical than is the demonstration of an effect of SSRIs for 
establishing a model’s predictive validity. Moreover, a lack of 
effect of SSRIs in a model does not necessarily demonstrate 
that it is not a model of OCD, since it might still be a model 
of compulsive behavior in the subgroup of OCD patients 
who do not respond to SSRIs.
Another important issue is that of response to acute versus 
chronic drug administration. Since, in OCD patients, both SRIs 
and SSRIs are effective only after some weeks of treatment, the 
predictive validity of those animal models that show beneficial 
effects after acute drug administration – as is usual in marble-
burying and signal attenuation tests – should be questioned.
Finally, it should be noted that evidence supporting the 
predictive validity of a model also strengthens its construct 
validity by suggesting similarities in the neural systems 
involved in both symptomatic manifestations.
Leading animal models of OCD
Depending on the method used to induce compulsive-like 
behavior, animal models of OCD are traditionally divided 
into four classes: genetic, pharmacological, behavioral 
manipulation, and neurodevelopmental.
Genetic models of OCD
Genetic animal models of OCD are not based on developing 
an animal with a known mutation related to OCD in humans, 
since such a clear genetic mutation has not been established 
in OCD. Rather, they are based on behavioral similarity, 
since the behavior of genetically modified mice has been 
proposed to be similar in specific aspects to that of OCD 
patients. There are currently seven mouse models of OCD 
in which compulsive-like behavior appears in mice follow-
ing a known genetic manipulation, and one model in which 
compulsive-like behavior developed as a result of selective 
breeding.48 However, these models have several limitations. 
On the one hand, genetically modified mice typically exhibit 
additional behavioral and neural abnormalities not related to 
OCD. For example, 5-HT2c receptor knockout (KO) mice 
show behavioral and neural abnormalities that may be related 
to cocaine dependence49 and Alzheimer’s disease,50 and they 
are obese and hyperphagic with an impaired satiety mecha-
nism.51 Similarly, dopamine transporter knockdown mice 
show behavioral abnormalities and response to treatment that 
may be relevant to attention deficit hyperactivity disorder, 
bipolar disorder, or substance use disorders.52 On the other 
hand, with the exception of Sapap3-mutant and Slitrk5 KO 
mice, there are no reports on the effects of pharmacological 
treatment on compulsive-like behavior of genetically modi-
fied mice. Due to these limitations, some authors argue that 
these models should not be considered real models of OCD, 
although they may contribute to our understanding of the role 
of certain genes in compulsive behavior.
DiCT-7 transgenic mice
DICT-7 mice, developed by Burton et al53 are transgenic 
mice expressing a neuropotentiating protein (cholera toxin 
A1 subunit) within a cortical-limbic subset of dopamine 
D1-receptor expressing (D1+) neurons. These mice were 
observed to exhibit abnormal behaviors, including episodes 
of perseverance or repetition of normal behaviors such as 
digging, grooming, and climbing, repetitive leaping, and non-
aggressive repeated biting of siblings during grooming.54
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Hoxb8 mutant mice
Hoxb8lox mutant mice, developed by Greer and Capecchi 
in 2002, have been reported to exhibit OCD-like increased 
persistence of self-directed grooming and body licking, as 
well as mutual grooming of other mice.55
5-HT2c receptor KO mouse
5-HT2c receptor KO mice were described by Chou-Green 
et al to display compulsive-like behavior, comprising more 
chewing of nonnutritive clay, a distinct pattern of neat 
chewing of plastic-mesh screen, and reduced habituation of 
head-dipping activity.56 These mice also showed enhanced 
reversal learning with a decrease in trials, correct responses, 
and omissions to criterion, supporting the involvement of 
5-HT2c receptors in the cognitive mechanism underlying 
spatial reversal learning.57
Dopamine transporter knockdown mouse
The dopamine transporter knockdown mouse (DAT-KD) is a 
mutant mouse with a genetic knockdown of the presynaptic 
dopamine transporter (DAT), which shows 10% normal DAT 
expression in dopamine neurons.58 This reduced expression 
impairs synaptic reuptake of dopamine, resulting in elevated 
(170%) levels of extracellular dopamine in the neostriatum 
(wild-type mice =100%). DAT-KD mutant mice show several 
types of behavioral evidence for high levels of dopamine acti-
vation: they tend to be hyperactive, to walk in perseverative 
straight paths, and to over-pursue certain incentive stimuli.59 
Compared with wild-type mice, DAT-KD mice exhibit more 
stereotyped and predictable syntactic grooming chains, 
designed as sequential super-stereotypy of a complex behav-
ioral pattern, an instinctive fixed action pattern that serially 
links up to 25 movements into four predictable phases that 
follow a single syntactic rule.58 It has been hypothesized that 
this phenomenon mimics overly rigid sequential patterns of 
movements, language, or thoughts that characterize several 
human brain disorders involving dysfunctional basal ganglia 
systems (ie, dopamine nigrostriatal projections to the neo-
striatum and related brain structures), such as pathological 
repetitions of spoken words in Tourette’s syndrome or the 
tormenting habits and thoughts of OCD.
Aromatase KO mice
Aromatase KO mice were originally developed to study the 
role of estradiol in the sexual differentiation of the reproduc-
tive system.60 They lack a functioning aromatase enzyme 
and are therefore estrogen-deficient. Male, but not female, 
KO mice exhibited increased wheel-running activity and 
grooming but decreased ambulatory activity.61 They also 
showed a decrease in catechol-O-methyltransferase activity in 
the hypothalamus. However, in addition to these compulsive-
like behaviors, these mice also show other behavioral abnor-
malities that have been linked with other disorders such as 
schizophrenia, for example, a decrease in pre-pulse inhibition 
and an increase in amphetamine-induced activity.62
Sapap3-mutant mice
SAP90/PSD95-associated protein 3 (SAPAP3) is a postsyn-
aptic scaffolding protein expressed mainly in the striatum. 
Sapap3 KO mice have defects in the structure of the post-
synaptic complex of cortico-striatal synapses63 and exhibit 
reduced cortico-striatal synaptic transmission and defects in 
the functioning of NMDA and AMPA glutamate receptors. 
Sapap3 KO mice, both males and females, show at the 
age of 4–6 months excessive self-grooming and increased 
anxiety-like behaviors on several tests, with no change in 
activity levels. These abnormal behaviors reduced with 
the intrastriatal injection of lentiviruses expressing the 
SAPAP3 protein.64 Interestingly, excessive self-grooming 
and anxiety-like behaviors in Sapap3 KO mice significantly 
improve following repeated (for 6 days) but not single 
injections of fluoxetine, supporting the predictive validity 
of the model.64
Slitrk5 KO mice
The Slitrk family of proteins is a family of integral membrane 
proteins that are thought to control neurite outgrowth during 
development.65 Slitrk5 KO mice show increased expression 
of FosB, indicating elevated neuronal activity, restricted to 
the OFC, as well as anatomical abnormalities in the striatum, 
including decreased volume, decreased dendritic complex-
ity of striatal neurons, and a reduced number of glutamate 
receptors. Slitrk5 KO mice develop excessive self-grooming, 
increased marble burying, and increased anxiety-like behav-
iors, manifested in the open field test and the elevated plus 
maze, with no gross motor deficits.66 The model has shown 
predictive value since excessive grooming in Slitrk5 KO mice 
was ameliorated by repeated administration over 21 days of 
fluoxetine.
In conclusion, the latter two genetic models of OCD are 
more valid than the initial ones, since both Sapap3-mutant 
and Slitrk5 KO mice exhibit a restricted profile of behav-
ioral and neural abnormalities that are relevant to OCD, 
and these altered behaviors improve in response to chronic 
administration of SSRIs. However, to increase their predic-
tive validity, it would be important to establish that drugs 
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without an anti-OCD effect do not significantly change the 
models. Moreover, due to the limited number of studies 
conducted so far, one cannot rule out the possibility that 
future research in these models might demonstrate additional 
behaviors or neural changes related with other disorders in 
addition to OCD.
Pharmacologically induced animal models 
of OCD
Pharmacological models are based on drug-induced behavioral 
alterations that are similar to specific OCD symptoms in 
humans, such as perseveration, indecision, or compulsive 
checking, as well as increased anxiety. Construct validity 
of these models is based on the fact that these abnormal 
behaviors are induced by manipulation of neurotransmitter 
systems that are thought to be related with OCD, mainly the 
serotonin and dopamine pathways. Two of the most widely 
studied animal models of OCD, the 8-OHDPAT-induced 
decreased alternation and quinpirole-induced compulsive 
checking models, belong to this group.
8-OHDPAT-induced decrease in spontaneous 
alternation
Yadin et al67 were the first to suggest that a pharmacologically 
induced decrease in the natural tendency of rats to explore 
novel places sequentially and in succession, what is known 
as spontaneous alternation, might serve to model two specific 
aspects of OCD, namely perseveration and indecision. The 
most common version of this model uses acute administration 
of the 5-HT1a agonist 8-OHDPAT to decrease spontaneous 
alternation both in rats and mice.68
Face validity of this model has been questioned because 
decreased alternation is common in neurological and psy-
chiatric conditions other than OCD (eg, Parkinson’s disease 
or schizophrenia), and it has been shown to result from 
an imbalance in many neurotransmitter systems including 
serotonin, dopamine, glutamate, gamma-aminobutyric acid, 
acetylcholine, and norepinephrine,69 as well as being linked 
to many different psychological processes70,71 (comprising 
sensory, attentional, emotional, and motor processes). The 
model nevertheless shows good predictive validity, supported 
by the fact that 8-OHDPAT-induced decreased alternation is 
prevented by both sub-chronic and chronic administration of 
the SSRI fluoxetine, ranging from three injections over 1 day 
to 48 injections over 21 days,67,72,73 as well as by sub-chronic 
administration (three injections over 1 day) of the SRI clomip-
ramine but not by sub-chronic administration of the tricyclic 
antidepressant desipramine.67,72 Results from lesions and deep 
brain stimulation are, however, controversial. On the one hand, 
Andrade et al74 detected that lesion of the thalamic reticular 
nucleus was as effective as clomipramine in attenuating the 
effects of 8-OHDPAT, whereas lesions of the OFC did not 
affect the model. Similarly, low- but not high-frequency stimu-
lation (HFS) of the thalamic nucleus was effective in reducing 
8-OHDPAT-induced perseveration in rats, whereas HFS of 
the STN has shown anti-OCD effects in humans.75
Regarding the construct validity of the model, this is 
supported by hormonal findings of 8-OHDPAT-induced 
decreased alternation being clearly modulated by fluctuating 
levels of endogenous ovarian hormones. In this context, 
decreased alternation is more robust in prepubertal male 
than in prepubertal female rats, but it did not differ between 
mature male and female rats. In mature females, the effect 
varied across the estrous cycle, it being nonsignificant 
during estrous and highest during the proestrous phase; it 
also changes during gestation, being high on day 17, low 
on day 21, and nonexistent during lactation.76 Discrepant 
findings have been obtained when assessing the interaction 
between ovarian hormones and the serotonergic system 
in 8-OHDPAT-induced decreased alternation,77 although 
non-conclusive results have been linked with the use of 
ovariectomized rats in these experiments, which may not 
constitute a good model for studying the role of ovarian 
hormones in females.
Neurosteroids, such as dehydroepiandrosterone (DHEA) 
or allopregnalone, have also been proposed to modulate the 
8-OHDPAT model, and a dysregulation of neurosteroids, 
including DHEA, dehydroepiandrosterone sulfate (DHEAS), 
cortisol, and corticotrophin-releasing factor, has been 
reported to be associated with OCD.78 From a construct valid-
ity perspective, but also supporting the predictive value of 
the model, the acute administration of 8-OHDPAT has been 
described to cause an 88% reduction in baseline serotonin 
levels, as assessed by spectrofluorometry, in the frontal cortex 
of mice. Chronic fluoxetine treatment after the single admin-
istration of 8-OHDPAT significantly increases the frontal 
cortex levels of serotonin, and this effect was dose-dependent, 
with increases ranging from around 70% for 5 mg/kg of 
fluoxetine treatment to 94% if the dose rises to 10 mg/kg. 
This is especially relevant since high – but not low – doses 
of fluoxetine have shown anti-OCD effect. Similarly, CREB 
levels in the frontal cortex were decreased by 32% with 
the acute administration of 8-OHDPAT, whereas chronic 
administration of fluoxetine raised them again. However, 
similar changes in both serotonin and CREB levels in the 
frontal cortex of 8-OHDPAT-treated mice were observed 
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after the administration of oxcarbamazepine, a drug that has 
not shown anti-OCD properties.68
Thus, although some results suggest that 8-OHDPAT-
induced decreased alternation may constitute an interesting 
animal model for screening anti-compulsive drugs and 
for studying the role of ovarian hormones in compulsive 
behavior, controversial findings, mainly from lesional and 
brain-stimulation studies, partially detract from the predictive 
and construct validity of the model.
Alkhatib et al79 recently reported that acute administration 
of 8-OHDPAT can also induce compulsive checking behavior 
in a large open field, as did quinpirole. However, differences 
in the mechanism of action of the two drugs and the appear-
ance of a distinct profile of effects on the amount and spatial 
distribution of locomotion suggest that this compulsive-like 
behavior might stem from dysfunctions in different parts of 
a specialized neural circuit.
Quinpirole-induced compulsive checking
This model, developed by Szechtman et al80 refers to the 
behavioral changes observed in rats after chronic treatment 
with the D2/D3 dopamine agonist quinpirole (0.5 mg/kg 
twice weekly for 5 weeks). When placed in a large open 
field with four small objects present at fixed locations, and 
over a period of 55 minutes in which they were videotaped, 
quinpirole-treated rats gradually developed a preference for 
two locations, at which they stopped more frequently (up to 
20 times more) than did saline-treated rats. They exhibited 
much shorter return times to these places and stopped at fewer 
places between returns, as compared with control rats.80,81 
In addition, quinpirole-treated rats perform a characteristic 
“ritual-like” set of motor actions at these preferred places/
objects, which were different from the actions performed 
at other locations/objects,82 and this pattern of activity was 
altered when the environmental properties of the places/
objects were changed. Thus, quinpirole rats are considered 
to exhibit a specific spatio-temporal organization of behavior 
with compulsive-like performance limited to certain pre-
ferred locations, whereas their behavior does not differ from 
that of saline-treated rats in other non-preferred locations.83 
According to Szechtman et al80,81 this behavior shares a formal 
conceptual framework/etiological criterion with compulsive 
checking in OCD, including a) a preoccupation with and an 
exaggerated hesitancy to leave the item(s) of interest, b) a 
ritual-like motor activity pattern, and c) dependence of check-
ing behavior on the environmental context. Some authors 
argue that the motivational bases of quinpirole-induced and 
OCD checking appear to be similar in that both represent an 
exaggerated form of normal checking of stimuli related to 
safety and security (the “home base” in the case of the rat 
model).67,80,83–86
Besides compulsive checking, quinpirole administration 
produces other perseverative, time-consuming, excessive, 
and rigid behaviors such as perseverative operant responding 
in the absence of reward,87 enhancement of excessive lever-
pressing in the condition of post-training signal attenuation,88 
and focusing on the response lever throughout the operant 
conditioning session.89 Intrastriatal injections of quinpirole 
elicit perseverative non-rewarded instrumental responses,90 
whereas intra-accumbens injections of the drug cause a 
general impairment of flexibility in a reversal learning task.91 
Quinpirole thus appears to reduce behavioral flexibility in 
coping with environmental stimuli by exaggerating adaptive 
strategies, which is in line with proposed models of OCD.
The model does, however, have some limitations. Behav-
ioral pattern analysis in Sprague Dawley rats revealed that, 
in comparison with OCD rituals in patients, quinpirole-
induced behavior consisted of a smaller behavioral repertoire 
performed with a high rate of repetition. Behavior in OCD 
patients is characterized not only by a high rate of repetition 
but also by the addition of nonfunctional unique acts, together 
referred to as pessimal behavior.92–94 Thus, only part of the 
behavioral characteristics of OCD (ie, repetition) is seen 
in quinpirole-induced behavior in rats.95 In this context, de 
Haas et al96 demonstrated that long-term quinpirole treat-
ment in C57BL/6J mice and Sprague Dawley rats resulted in 
increased repetition and a more limited behavioral repertoire, 
indicating a more stereotypic than compulsive-like behavior 
in quinpirole-treated rats. Whatever the case, recent data sug-
gest that genetic background might have an impact on the 
expression of quinpirole-induced compulsive-like behavior, 
since A/J, but not other, mice show a greater behavioral 
repertoire and also a high rate of behavioral repetition after 
the chronic administration of quinpirole, a behavioral pattern 
that resembles that of OCD rituals.96
Quinpirole-induced compulsive checking has been shown 
to be partially attenuated by chronic administration (daily 
injections over 5 weeks) of clomipramine,80 supporting 
the predictive validity of the model. Regretfully, no data 
are available for changes in the model in response to the 
administration of SSRIs or other antidepressants not effec-
tive in OCD. Lesional and stimulation studies also partially 
support the predictive validity of the quinpirole-induced 
compulsive checking model. HFS of the STN did not have 
any influence on checking behavior of saline-treated rats or 
on their locomotor activity, whereas in quinpirole-treated 
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rats, it transiently reduced compulsive behavior without 
affecting locomotion.97 Temporary inactivation of the STN 
after the administration of muscimol decreased locomotion – 
but not checking – in a dose-dependent way in saline-treated 
rats, whereas in quinpirole-treated ones, the lowest dose of 
muscimol had no effect, the intermediate dose decreased 
compulsive checking without affecting locomotion, and 
the highest dose decreased both checking and locomotion.98 
Similar to what has been described for HFS, these effects of 
the temporary inactivation of the STN on checking behavior 
were transient.97 HFS of the shell and core of the NAC did not 
have any influence on the checking behavior of saline-treated 
rats, but it did increase their locomotor activity, whereas in 
quinpirole-treated ones, it transiently reduced compulsive 
behavior without affecting locomotion.99 Finally, pharma-
cological inactivation and HFS of the entopeduncularis 
nucleus, the rodent equivalent of the human globus pallidus 
(GP) internus, and of the GP, the rodent equivalent of the 
human GP externus, exerted an anti-compulsive effect on 
quinpirole-sensitized rats but not on saline-treated ones, 
without affecting locomotion in any of them.100
Construct validity studies have demonstrated that 
activation of kappa receptors by the administration of 
a kappa opioid agonist, namely (5a,7a,8)-N-methyl-[7- 
(1-pyrrolidinyl)-1-oxaspirol[4.5]dec-8-yl]-benzeneacetamide 
(U69593), facilitated the development of quinpirole-induced 
compulsive checking, whereas treatment with the kappa ago-
nist on its own had no behavioral effect.19 Perreault et al101 
also found that treatment with either quinpirole or the kappa 
agonist or both increased the number of D2 and D3 recep-
tors in their high-affinity state in the NAC, as well as the 
number of high-affinity D2 receptors in the caudate putamen, 
supporting the role of these receptors and of the striatum in 
compulsive checking. On the other hand, negative results 
have been obtained for the effect of pituitary hormones, 
such as vasopressin, oxytocin, and adrenocorticotropin, on 
quinpirole-induced compulsive checking,102 partially com-
promising the construct validity of the model, since these 
hormones have been reported to be related with the severity 
of OCD.
Quinpirole-induced water contrafreeloading
Besides compulsive checking, repeated administration of 
quinpirole also produces an increase in contrafreeloading 
(CFL),103 a phenomenon that occurs when animals, offered 
a choice between working for food (for instance, by lever-
pressing) and obtaining it for free, consume a high propor-
tion of their food from the source which requires effort.104 
Alongside this increase in the fraction of water obtained by 
operant responding (percentage of CFL), quinpirole-treated 
mice show a reduction in the total amount of water intake, 
that is, hypodipsia. Administration of the serotonergic 
agent clomipramine prevents the development of both CFL 
and hypodipsia induced by quinpirole, while haloperidol, a 
classical antipsychotic with D2 antagonist activity, prevents 
CFL but not hypodipsia.105 Aripiprazole, a second-generation 
antipsychotic that acts as a dopaminergic stabilizer, shows, 
by contrast, no effect on either quinpirole-induced CFL or 
hypodipsia.105 Interestingly, therefore, the effects produced 
by repeated administration of a dopaminergic D2/D3 agonist 
seem to be more efficiently addressed by the action of a sero-
toninergic antidepressant, clomipramine, than by drugs that, 
albeit to a different extent, inhibit dopaminergic tone.
mCPP-induced directional persistence in reinforced 
spatial alternation
Administration of meta-chlorophenylpiperazine (mCPP), 
a nonspecific serotonin agonist, which mainly acts at the 
5-HT2c, 5-HT1d, and 5-HT1a receptors, increased direc-
tional persistence in a reinforced delayed alternation task. 
This mCPP-induced persistence was reduced by chronic 
administration of fluoxetine for 20 days but not by desip-
ramine or a benzodiazepine. Challenge with a 5-HT2c 
antagonist, but not a 5-HT2a antagonist or a 5-HT1b ago-
nist, reduced mCPP-induced persistence, thus underlining 
the importance of 5-HT2c receptors in this compulsive-like 
behavior.106
5-HT1bR agonist-induced behavior
Acute treatment with a serotonin 1b (5-HT1bR) receptor 
agonist induces OCD-like behaviors in female Balb/cJ mice, 
including reduced PPI, hyperlocomotion, and perseverative 
spatial locomotion patterns, which are reduced by chronic 
treatment (4 weeks) with fluoxetine and clomipramine but not 
with desipramine.107,108 5-HT1b receptors in the OFC appear 
to be necessary for the expression of OCD-like behaviors 
in this animal model. In this regard, whereas infusion of a 
5-HT1b antagonist specifically into the OFC blocked the 
behavioral effects of systemic administration of a 5-HT1b 
agonist, infusion of the same antagonist into the infralimbic 
cortex did not. Additionally, infusion of the 5-HT1b agonist 
into the OFC, but not into the infralimbic cortex, was able to 
induce some of the behavioral effects observed after systemic 
treatment.108 In this context, 5-HT1b agonists have been 
reported to exacerbate OCD symptoms in patients affected 
by the disorder.109 Thus, this model suggests that the 5-HT1b 
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receptor pathway might be a potential therapeutic target for 
new OCD treatments.
Behavioral manipulation-based animal 
models of OCD
This subgroup comprises what have been called “behavioral” 
and “cognitive” animal models of OCD. Behavioral models 
include 1) naturally occurring repetitive or stereotypic behav-
iors, such as fur chewing and weaving, and 2) innate motor 
behaviors that occur during periods of stress or conflict – 
displacement behaviors – such as grooming, cleaning, and 
pecking, or following some behavioral manipulation – 
adjunctive behaviors – such as schedule-induced polydipsia 
and food restriction-induced hyperactivity. Cognitive models 
attempt to capture specific neuropsychological features of 
OCD – reversal learning, impaired set-shifting and response 
inhibition, or altered habit learning – as well as their neu-
rochemical and neuroanatomical correlates. Three of the 
most widely studied animal models of OCD, namely marble 
burying, signal attenuation, and spontaneous stereotypy in 
deer mice, belong to this subgroup.
Marble burying in mice and rats
Inhibition of natural rodent behavior involving the burying 
of both noxious and harmless objects was originally hypoth-
esized to constitute a screening test for anxiolytic activity 
because the duration and extent of burying objects were 
reduced by different anxiolytic drugs. However, it was later 
argued that the model does not mimic anxiety but may rather 
be related to compulsive behaviors.110–114 Mice were found 
not to avoid marbles when given the opportunity to do so, 
suggesting that they have no aversive or fear-provoking 
properties,113 and repeated exposure to marbles did not lead 
to habituation of marble burying, indicating that this behavior 
was not related to novelty or fear.112,113
The marble-burying test is probably the most cost-effective 
animal model of OCD, since it requires no behavioral training 
and no pharmacological manipulation. Consequently, it is 
one of the most widely studied, alongside the 8-OHDPAT-
induced decreased alternation model that requires limited 
behavioral training and acute administration of 8-OHDPAT. 
There are many reports that burying behavior in male 
mice and rats is decreased by the administration of SSRIs 
at doses that do not affect locomotor activity,68,73,113,115–121 
and there is one study showing that such a suppressive 
effect is not exerted by desipramine.116 However, the well-
documented finding that burying behavior is also reduced 
by anxiolytic and anticonvulsant drugs that do not have 
anti-compulsive activity, such as diazepam, clonazepam, or 
oxcarbamazepine,68,113,117,119,122–125 undermines the predic-
tive validity of the model. Atypical antipsychotics such as 
olanzapine, quetiapine, and aripiprazole all reduce marble 
burying, but aripiprazole is the only one to do so without 
reducing locomotion and impairing motor coordination. 
Pharmacological manipulation seems to suggest that this 
effect may be exerted via either activation of 5-HT1a 
receptors or blockade of D2 receptors.125 This is especially 
interesting, since aripiprazole has recently demonstrated an 
anti-obsessional effect significantly greater than that of olan-
zapine or quetiapine.126 The administration of NMDA antago-
nists such as memantine, amantadine, or MK-801 to male 
mice also decreased marble burying without concomitantly 
decreasing locomotion, but the glutamate release inhibitor 
riluzole showed no effect on marble burying.115 Since both 
memantine and riluzole have shown anti-obsessional effect in 
OCD patients, these results again compromise the predictive 
validity of the model.
Regarding construct validity, ovarian and related hor-
mones have been reported to influence marble-burying behav-
ior. Normally, cycling female rats buried more marbles during 
the diestrous compared with the proestrous phase.118 Llaneza 
and Frye127 found that the time spent by cycling rats on marble 
burying was reduced in the proestrous compared with the 
diestrous phase, although the number of buried marbles did 
not differ between phases. Moreover, acute administration 
of progesterone, alone or in combination with estradiol, to 
ovariectomized rats decreased this burying time.
Neurosteroids also modified marble burying. Acute 
administration of allopregnalone or progesterone decreased 
marble burying in male mice, whereas DHEAS increased 
it, without locomotor activity being affected in any case.73 
Gonadotropin-releasing hormone also exerts an effect on 
marble burying that is mediated by its effect on seroton-
ergic activity, specifically through 5-HT2a/2c receptors.128 
Other serotonin receptors that seem to be involved in 
marble-burying behavior include 5-HT7.129 Intracellular Ca2+ 
likewise appears to play an important role in marble burying, 
since administration of calcium-channel antagonists attenu-
ates marble burying without any effect on locomotion.128 
Finally, sigma 1 receptors may also be implicated in marble-
burying behavior, and it has been hypothesized that they 
might mediate the effect of fluvoxamine but not of paroxetine 
on the reduction of this compulsive-like behavior.114
In conclusion, marble burying as an animal model of 
OCD shows good face validity but poor predictive validity, 
since it cannot differentiate between anti-compulsive and 
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anxiolytic drugs. Moreover, marble burying failed to detect 
the anti-compulsive activity of riluzole, suggesting that it may 
not be sensitive to all classes of anti-compulsive treatments. 
Consequently, this is not a suitable model for testing new 
anti-compulsive drugs.
The signal attenuation model
The signal attenuation model was developed by Joel in 
2006,130 based on the premise that compulsive behavior 
results from a deficit in the feedback associated with the per-
formance of normal goal-directed responses.131 In this model, 
the goal-directed behavior is lever-pressing for food, and the 
feedback cue is a stimulus that accompanies the delivery of 
food. To attenuate the signaling property of the stimulus, the 
latter is repeatedly presented without food, and the effects of 
this signal attenuation are finally assessed under extinction 
conditions (pressing the lever results in the presentation of the 
stimulus, but no food is delivered). To control for the effects 
of extinction per se, the behavior of these rats is compared 
with that of others in an extinction session that was not pre-
ceded by a signal attenuation process (regular extinction). 
An anti-compulsive effect in this model is evidenced when a 
decrease in the number of excessive lever presses is detected 
in rats that had undergone the signal attenuation process but 
not in those that only underwent regular extinction.
Acute administration of paroxetine and fluvoxamine 
exerted an anti-compulsive effect on the model, whereas acute 
administration of desipramine, diazepam, and haloperidol 
did not.132 However, no data are available for the effects of 
chronic administration of any medication on the signal attenu-
ation process, and hence, the predictive validity of the model 
remains limited.
Lesional studies showed that manipulation of the rat OFC 
affected compulsive lever-pressing.133 Specifically, lesions of 
the OFC were followed by an increase in compulsive lever-
pressing that was correlated with an increase in the density of 
the striatal serotonin transporter134 and a decrease in the content 
of dopamine and serotonin in the striatum. Intra-striatal admin-
istration of paroxetine abolishes orbitofrontal lesion-induced 
increased compulsivity.134 Lesions of the STN increased 
compulsive behavior and decreased dopamine and serotonin 
content in the striatum.135 Post-training temporary inactivation, 
as well as HFS, of the STN and of the entopeduncular nucleus 
of the GP also exerted an anti-compulsive effect.98,136 Gener-
ally, therefore, the results from lesional studies contribute to 
the predictive and construct validity of the model.
Also, with regard to construct validity, compulsive 
level-pressing has been reported to be modulated by ovarian 
hormones, with fluctuations in its level across the estrous 
cycle (higher in the late diestrous and lower during the estrous 
phase). Acute administration of estradiol to prepubertal female 
rats attenuates compulsive behavior, whereas withdrawal from 
chronic administration of estradiol increases it.137 Besides 
hormonal influences, manipulation of serotonergic activity, 
specifically through antagonism of 5-HT2c receptors, also 
shows an anti-compulsive effect. This effect was also present 
when the 5-HT2c antagonist was administered directly into 
the OFC of the rat, reinforcing the importance of this corti-
cal area for compulsive behavior.138 Dopamine receptors are 
also involved in compulsive lever-pressing, as demonstrated 
by the fact that withdrawal from repeated administration of a 
D1 antagonist or the D2 agonist quinpirole led to an increase 
in compulsive lever-pressing, whereas a D1 agonist or D2 
antagonist exerted no effect on the model.139 Finally, acute 
administration of d-cycloserine, a partial NMDA agonist, also 
decreased compulsive lever-pressing.140
Unfortunately, the signal attenuation model has a major 
shortcoming, namely that it is unable to test the effect of 
repeated administration of drugs, since this would affect the 
acquisition of the behavior in the early stages of the procedure 
(ie, lever-pressing training, signal attenuation).
Spontaneous stereotypy in deer mice
This model is based on the fact that deer mice (Peromyscus 
maniculatus bairdii) show spontaneous stereotypic behaviors 
consisting of vertical jumping, backward somersaulting, and 
patterned running.141 Depending on the frequency of these 
behaviors, deer mice can be classified into high-, low-, and 
non-stereotypic mice. Both high- and low-stereotypic deer 
mice have been used as models of OCD, in some studies 
comparing them with non-stereotypic ones. Although both 
male and female mice were used in the studies, the potential 
influence of sex on the results was not analyzed.
In terms of predictive validity, stereotypic behaviors in 
deer mice significantly decreased in response to repeated 
administration of fluoxetine but not of desipramine.142 
Systemic administration of the 5-HT2a/2c agonist mCPP 
and of the D2 agonist quinpirole also decreased stereotypic 
behaviors.142 This is an intriguing result, since mCPP worsens 
OCD symptoms in patients, and D2 antagonists (anti-
psychotics) but not agonists such as quinpirole are used as 
potentiating strategies in OCD. Finally, the same reduction 
in stereotypic behavior was observed when blocking striatal 
D1 and NMDA glutamate receptors.143
Regarding construct validity, high- compared with 
low-stereotypic mice showed decreased enkephalin content 
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and an increased dynorphin/enkephalin ratio in the striatum. 
It has been hypothesized that high stereotypy may be related to 
an imbalance in the functioning of the direct and indirect basal 
ganglia-thalamo cortical pathways, with a preponderance of 
the direct one.142 Low- and high-stereotypic mice, compared 
with non-stereotypic ones, showed elevated levels of cyclic 
adenosine monophosphate (cAMP) in the frontal cortex but 
not in the striatum, suggesting that the frontal cortex is also 
involved in stereotypic behaviors. In this context, chronic 
administration of fluoxetine for 21 days decreased these 
elevated cAMP levels in the frontal cortex of high-stereotypic 
mice at the same time as reducing stereotypic behaviors.144
With respect to face validity, however, it is important to 
note that stereotypic behaviors are present in many neuropsy-
chiatric conditions other than OCD, including schizophrenia, 
autism, or mental retardation.
Schedule-induced polydipsia
This model is based on the observation that food-deprived rats 
trained to collect a food reward on a fixed-interval schedule, 
while having free access to drinking water, develop after 
3–5 weeks of training a polydipsic behavior and consume five 
to ten times more water than control rats that were not exposed 
to this reinforcement schedule.145 Since it can be described 
as repetitive, excessive, and inappropriate, schedule-induced 
polydipsia could therefore be considered a compulsive-like 
condition.
Predictive validity of the model is established by the 
fact that, in male rats, schedule-induced polydipsia, but not 
drinking in control rats, is reduced by chronic administration 
of clomipramine, fluoxetine, and fluvoxamine but does not 
change in response to chronic administration of desipramine, 
haloperidol, or diazepam.145 High- but not low-frequency 
stimulation of the NAC shell, the mediodorsal thalamic 
nucleus, and the bed nucleus of the stria terminalis also 
reduced polydipsic behavior in male rats, although the effects 
of stimulation on drinking in normal rats were not assessed, 
limiting the interpretation of the results.146
Schedule-induced polydipsia is modulated by serotoner-
gic agents, a fact that supports the construct validity of the 
model. Acute administration of different 5-HT2c agonists 
decreased polydipsic behavior in male and female rats 
without affecting the amount of water consumed by control 
rats.147 Administration of a 5-HT1a antagonist or a 5-HT1b 
partial agonist with fluoxetine accelerated the effect of the 
SSRI on reducing polydipsic behavior in male rats, while 
administration of the serotonergic antagonist or agonist alone 
had no effect on the model.148
Neurodevelopmental animal models 
of OCD
Neonatal clomipramine
In 2010, Andersen et al claimed to have developed a multiple 
OCD-like behavior model in rats.149 They compared rats 
treated with 16 intraperitoneal injections of 15 mg/kg of 
clomipramine administered across postnatal days 9–16 with 
those receiving a saline vehicle following the same pattern 
of administration. Clomipramine-exposed rats showed more 
anxiety-like behavior in the elevated plus maze and a directed 
anxiety response in the marble-burying task, burying more 
foreign/novel objects. They also showed more perseveration 
in a reversal task, a general impairment of discrimination 
learning, and increased hoarding behavior. Besides these 
behavioral changes, regional biochemical differences were 
also observed in rats exposed to clomipramine, namely 
increased RNA messenger expression for 5-HT2c recep-
tors in the OFC and D2 receptors in the striatum. None of 
these behavioral or biochemical changes were detected if 
clomipramine was administered in adult rats at postnatal 
days 50–57.
Animal models and fear conditioning
Recent translational research suggests that dysfunctional 
fear acquisition and extinction learning may be at the core 
of many anxiety disorders including OCD as well as of their 
response to exposure-based therapies.150 Extensive literature 
on animal models addressing the neural mechanisms of fear 
acquisition and extinction has allowed improving our knowl-
edge of the mechanism of action underlying exposition and 
response prevention (ERP), the first-line treatment for OCD 
and a psychological therapy based on extinction processes.151 
Rodent models have probed that while amygdala plays a 
critical role in the acquisition and expression of conditioned 
fear, prefrontal areas including the ventromedial PFC and 
medial, dorsomedial, and dorsolateral PFC are important 
for consolidation, retention, and expression of extinction 
memory.152 Differences in cortical thickness and volume of 
these areas have been described to be related to exposure 
therapy outcome in OCD patients.153 Since strong parallels 
exist between fear circuits in rodents and humans, transla-
tional research in the last decade has focused on developing 
strategies that facilitate extinction of fear, through pharma-
cological, physical, behavioral, or cognitive treatments that 
combined with ERP can aid in extinction learning. In terms 
of pharmacological manipulations, infusion in rat amygdala 
of an NMDA antagonist blocks extinction,154 while admin-
istration of d-cycloserine, an NMDA partial agonist, seems 
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to facilitate extinction both in rats155 and in OCD patients.11 
Deep brain stimulation as well as repetitive transcranial 
magnetic stimulation of the VS in rats during extinction 
training reduced fear expression and strengthened extinction 
memory facilitating fear extinction.156 Future research should 
address whether these physical techniques might augment the 
effectiveness of ERP in OCD patients. Behavioral manipula-
tion based on extinction training during the reconsolidation 
period – through the presentation of an isolated retrieval 
trial before the extinction session – has also been probed to 
induce a persistent reduction in learned fear both in rats157 
and healthy subjects158 and might constitute a challenging 
option for OCD patients resistant to classical ERP.
Conclusion
Many animal models have been generated in the last decades 
to explore different aspects associated with OCD from a 
range of perspectives, including pharmacological manipula-
tion, genetic selection, and the analysis of behavioral patterns 
or neurocognitive function.159 The aim of all these approaches 
is to improve our understanding of the etiopathogenic basis 
of the disorder and to develop new therapeutic strategies, a 
particularly important goal considering the high percentage 
of OCD patients with partial or no response to available 
therapies. A key aspect to consider in relation to the so-called 
animal models of OCD is the term itself, since the models 
presented in this review should, in our view, be regarded not 
as models of OCD per se but, rather, as animal models of cer-
tain psychopathological processes that are present not only in 
OCD but also in other psychiatric or neurological disorders; 
examples of these processes would be compulsivity, stereo-
typy, and perseverance. In this regard, animal models might 
help to study from a trans-diagnostic perspective the neural 
mechanisms that contribute to common, specific aspects of 
different mental disorders. With this aim in mind, it should 
be noted that researchers have yet to develop an optimum 
animal model of compulsivity or perseverance, that is, one 
that shows a sufficient degree of construct, predictive, and 
face validity. In genetic models, for instance, compulsive-
like symptoms are associated with other symptoms not 
characteristic of OCD, such as obesity or hyperphagia, and 
very little is known about how these symptoms might be 
modified by the administration of drugs with or without an 
anti-obsessive action. One of the limitations of models based 
on pharmacological manipulation – which include two of 
the most well-known animal models of OCD, namely the 
8-OHDPAT-induced decreased alternation model and the 
quinpirole-induced compulsive checking model – is that they 
mainly mimic just one specific aspect of compulsive-like 
behavior: perseverance. The issue here is that perseverant 
behavior is also frequently observed in other neurological 
and psychiatric disorders such as Parkinson’s disease and 
schizophrenia, which are distinct from OCD. A further 
problem is that lesional studies have produced contradictory 
findings, thus limiting both the construct and the predictive 
validity of the models. Finally, the subgroup of behavioral 
models includes what is probably the most cost-effective 
animal model of OCD, the marble-burying test. However, 
from a translational point of view, this model has proved to 
be of very limited value when it comes to developing new 
pharmacological strategies, whether due to its inability to 
discriminate between the effect of anxiolytic drugs or due to 
the methodological impossibility of analyzing the repeated 
administration of drugs. It should be highlighted, however, 
that behavioral models have shed some light on certain etio-
pathogenic aspects of compulsive-like behavior, especially 
as regards the effect which hormonal factors have on it. 
Combining several animal models of OCD in order to detect 
anti-compulsive activity of new drugs might therefore con-
stitute an interesting therapeutic option. The area of research 
where convergence is greatest involves the role of ovarian 
and related hormones in compulsive behavior. Fluctuations in 
compulsive behavior during the estrous cycle show an oppo-
site pattern in the marble-burying and 8-OHDPAT models, 
but the administration of exogenous sex hormones exerted 
similar effects in the two models in ovariectomized females 
and in intact males. Therefore, new treatment strategies for 
OCD could explore the role of sex hormones in compulsive 
behavior. Some recent results suggest that the blockade of D1 
and NMDA receptors might also constitute a good alternative 
focus for research. Animal models can likewise be used to 
detect new brain regions whose electrical stimulation may 
produce an anti-compulsive effect, thus paving the way for 
the development of a promising new technique that is still at 
the early stages of implementation: deep brain stimulation.
Finally, although behavioral similarities between animals 
and humans will be always limited and partial, animal models 
may constitute a unique opportunity to assess neurocognitive 
deficits that have been hypothesized to underlie the etiopatho-
genesis of OCD. Indeed, the use of suitable animal models 
designed especially to assess tasks that can be evaluated both 
in humans and rats, such as the stop-signal reaction time 
and the intradimensional/extradimensional shift tasks, could 
constitute a genuine alternative approach to disentangling the 
complex etiology of OCD.
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